Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone

被引:11
|
作者
Palomba, S [1 ]
Morelli, M [1 ]
Di Carlo, C [1 ]
Noia, R [1 ]
Pellicano, M [1 ]
Zullo, F [1 ]
机构
[1] Univ Catanzaro, Dept Obstet & Gynecol, Chair Obstet & Gynecol, Catanzaro, Italy
关键词
GnRH-a; tibolone; bone loss; BMD; postmenopause; analog; leiomyoma;
D O I
10.1016/S0015-0282(02)03149-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To study the bone metabolism in postmenopausal women who have been treated with gonadotropin-releasing hormone agonist (GnRH-a) and tibolone. Design: Prospective, open. controlled clinical trial. Setting: Department of Gynecology and Obstetrics, University of Catanzaro, Catanzaro, Italy. Patient(s): One hundred twenty perimenopausal women with symptomatic uterine leiomyomas (groups A and 13), and 40 healthy control women who underwent a normal spontaneous menopause (group C). Intervention(s): Treatment for 12 months with leuprolide acetate plus tibolone (group A) or hysterectomy with bilateral oophorectomy (group B). Main Outcome Measure(s): Lumbar spine bone mineral density (BMD) and bone turnover markers at entry into the study, after medical treatment (only group A), and 12 months after discontinuation medical treatment (group A) or after surgery (group 13). The same parameters were noted in healthy women before and 12 months after menopause (retrospective control group, group C). Result(s): At the women's entry into the study, no significant difference in BMD and bone turnover markers was detected between groups A and B. In group A. no significant variation in BMD or bone turnover markers was observed 12 months after medical treatment in comparison with baseline. At 12 months after discontinuation of treatment (in women who had achieved menopause) and after surgery, we observed a statistically significant decrease in BMD and in bone turnover markers in both groups in comparison with baseline. At 12 months after they became menopausal, we also observed a statistically significant reduction in BMD and in bone turnover markers in control group C. At the same 12-month follow-up visit, a statistically significant difference in BMD and in bone turnover markers was detected when comparing groups A and B with group C. Conclusion(s): Women previously treated with GnRH-a and tibolone similar to women who are menopausal as a result of surgery, have higher bone loss after menopause. (C) 2002 by American Society for Reproductive Medicine.
引用
收藏
页码:63 / 68
页数:6
相关论文
共 50 条
  • [31] Intestinal endometriosis without evident pelvic foci treated with gonadotropin-releasing hormone agonist
    Porpora, MG
    Pallante, D
    Ferro, A
    Crobu, M
    Cerenzia, P
    Panici, PLB
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2006, 125 (02) : 265 - 266
  • [32] Aggressive angiomyxoma of the vulva treated by using a gonadotropin-releasing hormone agonist: a case report
    Lee, C. W.
    Yoon, J. H.
    Park, D. C.
    Lee, S. J.
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2011, 32 (06) : 686 - 688
  • [33] Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist
    Laffin, Luke J.
    Jafar, Munnam S.
    Bakris, George L.
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2017, 19 (11): : 1202 - 1203
  • [34] Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy
    Ripps, BA
    VanGilder, K
    Minhas, B
    Welford, M
    Mamish, Z
    [J]. JOURNAL OF REPRODUCTIVE MEDICINE, 2003, 48 (10) : 761 - 766
  • [35] Gonadotropin-releasing hormone gene expression is increased in the medial basal hypothalamus of postmenopausal women
    Rance, NE
    Uswandi, SV
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10): : 3540 - 3546
  • [36] Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists
    Stoch, SA
    Parker, RA
    Chen, LP
    Bubley, G
    Ko, YJ
    Vincelette, A
    Greenspan, SL
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (06): : 2787 - 2791
  • [37] A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea
    Ji, Miaomiao
    Yuan, Ming
    Jiao, Xue
    Li, Qiuju
    Huang, Yufei
    Li, Jing
    Wang, Guoyun
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2022, 38 (02) : 164 - 169
  • [38] Surgery, gonadotropin-releasing hormone agonist downregulation and in vitro fertilisation in women with infertility and endometriomas
    Bergenheim, Sara J.
    Perlman, Signe
    Banner-Voigt, Marie Louise V. C.
    Dalsgaard, Torur
    Pedersen, Anette T.
    Andersen, A. Nyboe
    Pinborg, Anja
    Lossl, Kristine
    [J]. DANISH MEDICAL JOURNAL, 2020, 67 (09):
  • [39] USE OF A GONADOTROPIN-RELEASING HORMONE AGONIST TO MANAGE PERIMENOPAUSAL WOMEN WITH SYMPTOMATIC UTERINE MYOMAS
    Wang, Peng-Hui
    Lee, Wen-Ling
    Cheng, Ming-Huei
    Yen, Ming-Shyen
    Chao, Kuan-Chong
    Chao, Hsiang-Tai
    [J]. TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2009, 48 (02): : 133 - 137
  • [40] Treatment of infertile women with adenomyosis with a conservative microsurgical technique and a gonadotropin-releasing hormone agonist
    Wang, PH
    Yang, TS
    Lee, WL
    Chao, HT
    Chang, SP
    Yuan, CC
    [J]. FERTILITY AND STERILITY, 2000, 73 (05) : 1061 - 1062